Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get in-depth healthcare industry analysis with the unparalleled resources at Informa Pharma Intelligence.
Download your copy of this essential whitepaper, which provides a window into the rapidly evolving world of personalized medicine, and the accompanying outlook for related clinical trials.
One Size No Longer Fits All: The Personalized Medicine Trial Landscape includes:
Scrip
By Mandy Jackson 17 Jan 2020
Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.
Skipta
17 Jan 2020
Explore the challenges in digital marketing that can make it difficult for you to directly connect with your specific target audience. Let Skipta’s exclusive perspectives be your guide.
Pink Sheet
By Brenda Sandburg 16 Jan 2020
An interactive timeline shows the news of the past decade and the evolution of US FDA policies. Click on each year for a full list of events and see the accompanying article.
Topic FDA Policy and regulation
Scrip
By Joseph Haas 15 Jan 2020
Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.
Scrip
By Jung Won Shin 15 Jan 2020
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.
Topic Clinical Trials Deal trends
Generics Bulletin
By Aidan Fry 15 Jan 2020
California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.
HBW Insight
15 Jan 2020
In addition to Sanofi, firms recalling OTC ranitidine products with documentation included in FDA's database updates through 9 January are Amneal Pharmaceuticals, Preferred Pharmaceuticals, which distributed products made by Amneal, and Granules India Ltd.
HBW Insight
By Tom Gallen 15 Jan 2020
Bayer has teamed up with skin microbiome specialist Azitra to develop consumer health products for a host of conditions.
Pink Sheet
By Ian Schofield 15 Jan 2020
Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019.
Pink Sheet
By Derrick Gingery 15 Jan 2020
The former US FDA principal deputy commissioner argues that accelerated approval, fast track and breakthrough designation standards may need updating, along with orphan and pediatric exclusivity requirements, to enhance the programs' efficacy.
Medtech Insight
By Shawn M. Schmitt 15 Jan 2020
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this first installment of a 10-part series, a procedure for hosting inspections is addressed.
Medtech Insight
By Marion Webb 15 Jan 2020
Amy Abernethy, FDA's principal deputy commissioner, sat down with Medtech Insight during CES 2020 to discuss the agency's progress on the Technology Modernization Action Plan, the pre-certification program for digital health products, and the FDA's plans for 2020.
Topic Digital Health FDA
Citeline
10 Jan 2020
Get a deeper understanding of breast cancer clinical trials initiated since 2014 and what the trends have meant for strategies in this area, with this free whitepaper from Citeline.
Topic Cancer Clinical Trials Research
HBW Insight
By Tom Gallen 09 Jan 2020
An interactive timeline of HBW Insight's coverage of the blossoming European CBD market in 2019. The timeline covers the main events of the year beginning with the European Commission's decision to classify CBD as a novel food, and ending on the filing of the first application for a synthetic form of the cannabis-derived ingredient.
HBW Insight
By Eileen Francis 08 Jan 2020
Perrigo's Ranir division purchased the brand, which includes a portfolio of antibacterial toothbrush protectors, children’s products and tongue cleaners, for an undisclosed amount from Bonfit America.
Pink Sheet
12 Dec 2019
Scrip
12 Dec 2019
Pink Sheet
12 Dec 2019
In Vivo
12 Dec 2019
Medtech Insight
12 Dec 2019
Scrip
12 Dec 2019
Pink Sheet
12 Dec 2019
Pink Sheet
12 Dec 2019
In Vivo
12 Dec 2019
Pink Sheet
12 Dec 2019
Pink Sheet
12 Dec 2019
Medtech Insight
12 Dec 2019
Pink Sheet
12 Dec 2019
Medtech Insight
12 Dec 2019
Scrip
12 Dec 2019
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
